MedTrace Logo

A Phase 1 Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of XEN-101

NCT05667129 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2023-07-20

No results posted yet for this study

Summary

The goal of this study is to assess the safety and tolerability of single and multiple ascending doses of XEN-101

Conditions

  • Healthy

Interventions

DRUG

XEN-101

Capsule formulation

DRUG

Placebo

capsule formulation

Sponsors & Collaborators

  • Xeno Biosciences

    lead INDUSTRY

Principal Investigators

  • Geza Lakner, MD · Clinical Research Units Hungary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2023-05-30
Completion
2023-05-30
FDA Drug
Yes

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05667129 on ClinicalTrials.gov